Anne John Michael – Medical News Asia

About Anne John Michael

This author has not written his bio yet.
But we are proud to say that Anne John Michael contributed 2 entries already.

Entries by Anne John Michael

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Gastrointestinal Cancer, Conferences, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.